![]()
|
|
||||||||
J. Biol. Chem., Vol. 278, Issue 51, 51243-51250, December 19, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
352 as a Magnesium Ligand*


¶
||
From the
Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109-1055
Protein farnesyltransferase (FTase) catalyzes the addition of a farnesyl chain onto the sulfur of a C-terminal cysteine of a protein substrate. Magnesium ions enhance farnesylation catalyzed by FTase by several hundred-fold, with a KMg value of 4 mM. The magnesium ion is proposed to coordinate the diphosphate leaving group of farnesyldiphosphate (FPP) to stabilize the developing charge in the farnesylation transition state. Here we further investigate the magnesium binding site using mutagenesis and biochemical studies. Free FPP binds Mg2+ with a Kd of 120 µM. The 10-fold weaker affinity for Mg2+ observed for the FTase·FPP·peptide ternary complex is probably caused by the positive charges in the diphosphate binding pocket of FTase. Furthermore, mutation of aspartate
352 to alanine (D
352A) or lysine (D
352K) in FTase drastically alters the Mg2+ dependence of FTase catalysis without dramatically affecting the rate constant of farnesylation minus magnesium or the binding affinity of either substrate. In D
352A FTase, the KMg increases 28-fold to 110 ± 30 mM, and the farnesylation rate constant at saturating Mg2+ decreases 27-fold to 0.30 ± 0.05 s-1. Substitution of a lysine for Asp-
352 removes the magnesium activation of farnesylation catalyzed by FTase but does not significantly enhance the rate constant for farnesylation in the absence of Mg2+. In wild type FTase, Mg2+ can be replaced by Mn2+ with a 2-fold lower KMn (2 mM). These results suggest both that Mg2+ coordinates the side chain carboxylate of Asp-
352 and that the role of magnesium in the reaction includes positioning the FPP prior to catalysis.
Received for publication, August 20, 2003 , and in revised form, October 7, 2003.
* This work was supported in part by National Institutes of Health Grant GM40602 (to C. A. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by National Institutes of Health Training Grant GM08597.
¶ Supported by National Institutes of Health Postdoctoral Training Grant F32 CA84757.
|| To whom correspondence should be addressed: 930 N. University Ave., Ann Arbor, MI 48109-1055. Tel.: 734-936-2678; Fax: 734-647-4865; E-mail: fierke{at}umich.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley Farnesyl transferase inhibitor resistance probed by target mutagenesis Blood, September 15, 2007; 110(6): 2102 - 2109. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Lane and L. S. Beese Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I J. Lipid Res., April 1, 2006; 47(4): 681 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Sousa, P. A. Fernandes, and M. J. Ramos Farnesyltransferase--New Insights into the Zinc-Coordination Sphere Paradigm: Evidence for a Carboxylate-Shift Mechanism Biophys. J., January 1, 2005; 88(1): 483 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Hartman, K. E. Bowers, and C. A. Fierke Lysine {beta}311 of Protein Geranylgeranyltransferase Type I Partially Replaces Magnesium J. Biol. Chem., July 16, 2004; 279(29): 30546 - 30553. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |